340B Hospitals Could See Audits On Use Of Drug Price Savings Under Biden Administration Proposal
Legislation would be needed and will be complicated to develop. While the effectiveness of existing audits has been question by a federal government watchdog, the proposal in Biden’s budget document suggests the administration has some sympathy with drug sponsors’ position in the ongoing fight over the 340B drug discount program.
You may also be interested in...
Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.
340B Fight Escalates As Biden Administration Seeks Refunds From Manufacturers, Threatens Them With Fines
Lilly, AstraZeneca, Novartis, Sanofi, Novo Nordisk and United Therapeutics ordered by HRSA to resume discounts to 340B contract pharmacies and refund past 'overcharges.'
House Energy and Commerce Committee releases US Government Accountability Office analysis of 340B contract pharmacies.